Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Filings indexed 767 across all filing types
Latest filing 2025-01-13 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-01-13 English
Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the total number of voting rights following a recent issuance of common stock. This type of filing is a standard regulatory disclosure required by stock exchanges (in this case, the LSE) to inform shareholders of changes in share capital for the purpose of calculating notification thresholds. It fits the definition of a 'Share Issue/Capital Change' (SHA) announcement.
2025-01-02 English
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director (John Johnston) exercising options and selling shares of MaxCyte, Inc. The text includes the standard PDMR disclosure tables required by regulatory bodies. This falls directly under the 'Director's Dealing' category.
2024-12-31 English
Director's Dealing 2024
Director's Dealing
2024-12-30 English
8-K
Regulatory Filings
2024-12-27 English
Regulatory Filings 2024
Regulatory Filings
2024-12-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.